Abstract

ROLE OF SINGLE IMMUNO-ONCOLOGY AGENTS AND COMBINATIONS IN CANCER THERAPY

Mobin P. Chacko*, Swathy N. S., Prasobh G. R. and Grace N. Raju

Abstract

Immuno-oncology is a developing and progressing treatment method that has immunotherapies designed to tackle the patient’s own system. Combining or sequencing immunotherapies that focus on distinct immune pathways may be a logical approach, with the potential to further enhance the magnitude of the antitumor immune reaction over single agents. Cancer immunotherapy has reached a juncture now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 kinds of cancers and 1 tissue-agnostic cancer indication. This particular approach is being viewed and researched for its potential effectiveness to improve and enhance longterm life-span or survival across multiple tumor types. It is important to design layout and work on how immunotherapies could also be most effectively useful to achieve the simplest possible patient outcomes. In this article, we highlight the old and new waves of IO therapy development, and supply perspectives on the newest momentum shifts in cancer immunotherapy.

Keywords: Immuno-oncology, Immune checkpoint inhibitor, Tumor microenvironment, PD-1, PD-L1, CTLA-4, CAR-T.